QUBT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Quantum Computing Inc. (QUBT) does not present a strong buy opportunity for a beginner, long-term investor at this time. While the stock has seen recent pre-market gains and has potential in the quantum computing space, the financial performance, insider selling, and lack of proprietary trading signals suggest caution. Holding off for clearer long-term growth signals or improved financials would be prudent.
The MACD histogram is positive at 0.271, suggesting bullish momentum, but it is contracting. RSI at 54.694 is neutral, indicating no strong overbought or oversold conditions. Moving averages are converging, showing no clear trend. Key resistance levels are at 9.912 and 10.712, while support levels are at 7.322 and 6.522. Pre-market price is above the pivot level of 8.617, indicating short-term bullishness.
Analysts from Northland initiated coverage with an Outperform rating and a $20 price target, citing the significant market potential of quantum computing.
Hedge funds have increased their buying activity by 185.71% over the last quarter.
Quantum computing stocks have gained strong investor interest, with potential for high returns in the long term.
Insiders have significantly increased selling activity by 1713.17% in the last month, which could indicate a lack of confidence in the stock's near-term performance.
Financial performance in Q4 2025 showed a significant drop in net income (-96.96% YoY), EPS (-97.87% YoY), and gross margin (-190.24% YoY).
News of potential fiduciary breaches being investigated by Purcell & Lefkowitz LLP could impact investor confidence.
In Q4 2025, revenue increased by 219.35% YoY to $198,000, indicating growth potential. However, net income dropped by 96.96% YoY to -$1,556,000, and EPS fell by 97.87% YoY to -$0.01. Gross margin also declined significantly by 190.24% YoY to -49.49%, highlighting profitability challenges.
Northland initiated coverage with an Outperform rating and a $20 price target, citing reduced execution risk at the industry level and significant market potential. Cantor Fitzgerald, however, lowered its price target from $15 to $10, maintaining a Neutral rating, reflecting mixed sentiment among analysts.
